Cartesian Therapeutics, Inc.
NASDAQ:RNACBiotechnology
Healthcare
$6.30 -4.15%
-$0.41 today
- Market cap
- $192.17M
- Beta
- 0.78
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.65
52W Low $5.60High $15.57
Volume 0.17M
Average 0.26M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$73.94M
FY 2025 · Annual
Investing Cash Flow
-$5.45M
FY 2025 · Annual
Financing Cash Flow
-$8.05M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (25.69M) | 35.38M | (219.71M) | (77.42M) | (130.3M) |
| Depreciation & Amortization | 1.25M | 1.29M | 843K | 1.15M | 2.96M |
| Deferred Income Tax | 2.4M | (21.4M) | (19M) | 287K | (9.19M) |
| Stock-Based Compensation | 7.72M | 11.19M | 22.52M | 6.58M | 10.52M |
| Change in Working Capital | (48.19M) | (60.38M) | 4.97M | (5.79M) | (8.06M) |
| Accounts Receivables | (2.69M) | 3.32M | 907K | 7.98M | (243K) |
| Inventory | 211K | 920K | 0 | 0 | 0 |
| Accounts Payables | (219K) | 92K | 2.83M | (2.93M) | 1.07M |
| Other Working Capital | (45.5M) | (64.71M) | 1.23M | (10.84M) | (8.89M) |
| Other Non-Cash Items | 2.13M | 2.29M | 159.21M | 51.52M | 60.14M |
| Operating Cash Flow | (60.38M) | (31.63M) | (51.16M) | (23.67M) | (73.94M) |
| Capital Expenditures | (1.09M) | (1.2M) | (206K) | (9.09M) | (5.45M) |
| Acquisitions (Net) | 0 | 0 | 6.56M | 351K | 0 |
| Purchases of Investments | (32.46M) | (33.5M) | 0 | 0 | 0 |
| Sales of Investments | 16.4M | 19.7M | 28.25M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (17.14M) | (15M) | 34.61M | (8.74M) | (5.45M) |
| Debt Repayment | 0 | 0 | (27.46M) | 0 | 0 |
| Common Stock Issued | 51.96M | 38.98M | 0 | 124.44M | (301K) |
| Common Stock Repurchased | 0 | 0 | (6.17M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 939K | 235K | 231K | 3.99M | (7.75M) |
| Financing Cash Flow | 52.9M | 39.22M | (13.15M) | 168.43M | (8.06M) |
| Effect of Forex Changes | (3K) | 20K | (53K) | (21K) | 45K |
| Net Change in Cash | (24.63M) | (7.4M) | (29.75M) | 135.99M | (87.41M) |
| Free Cash Flow | (61.47M) | (32.83M) | (51.37M) | (32.77M) | (79.4M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$130.3M
+ D&A$3.0M
+ Stock-Based Comp$10.5M
- Deferred Tax-$9.2M
- Working Capital-$8.1M
+ Other Non-Cash$60.1M
= Operating Cash Flow-$73.9M
- Capex-$5.5M
= Free Cash Flow-$79.4M
Analysis
FY2025 free cash flow is -$79.4M. FCF conversion is 60.9% of net income. Operating cash flow was -$73.9M, with capex of -$5.5M. The largest bridge item is Other Non-Cash at $60.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Sep 29, 2026 | |
| SC 13G | SC 13G filing | Aug 13, 2026 |
Does RNAC generate free cash flow?
Cartesian Therapeutics, Inc. (RNAC) generated -$79.39M of free cash flow in fiscal 2025.
How much operating cash flow does RNAC produce?
Operating cash flow was -$73.94M, before capital expenditures of $5.45M.
Continue the stock analysis
Jump to another research area for this company.